ZA200802667B - Argatroban formulation - Google Patents

Argatroban formulation

Info

Publication number
ZA200802667B
ZA200802667B ZA200802667A ZA200802667A ZA200802667B ZA 200802667 B ZA200802667 B ZA 200802667B ZA 200802667 A ZA200802667 A ZA 200802667A ZA 200802667 A ZA200802667 A ZA 200802667A ZA 200802667 B ZA200802667 B ZA 200802667B
Authority
ZA
South Africa
Prior art keywords
argatroban
formulation
argatroban formulation
solubilize
aqueous
Prior art date
Application number
ZA200802667A
Other languages
English (en)
Inventor
Owoo George
Richard A Burgos
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of ZA200802667B publication Critical patent/ZA200802667B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200802667A 2005-09-01 2008-03-26 Argatroban formulation ZA200802667B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71340305P 2005-09-01 2005-09-01

Publications (1)

Publication Number Publication Date
ZA200802667B true ZA200802667B (en) 2009-01-28

Family

ID=37809398

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802667A ZA200802667B (en) 2005-09-01 2008-03-26 Argatroban formulation

Country Status (23)

Country Link
US (3) US7642271B2 (fr)
EP (1) EP1948133B1 (fr)
JP (1) JP5189980B2 (fr)
KR (3) KR20080042155A (fr)
CN (2) CN102895179B (fr)
AT (1) ATE514416T1 (fr)
AU (1) AU2006285097B2 (fr)
BR (1) BRPI0616127B8 (fr)
CA (1) CA2617920C (fr)
CY (1) CY1112109T1 (fr)
DK (1) DK1948133T3 (fr)
ES (1) ES2368758T3 (fr)
HK (2) HK1123193A1 (fr)
IL (2) IL189290A (fr)
IN (1) IN2015DN03947A (fr)
MX (1) MX2008002177A (fr)
NZ (1) NZ565821A (fr)
PL (1) PL1948133T3 (fr)
PT (1) PT1948133E (fr)
RU (1) RU2416393C2 (fr)
SI (1) SI1948133T1 (fr)
WO (1) WO2007027565A2 (fr)
ZA (1) ZA200802667B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027565A2 (fr) * 2005-09-01 2007-03-08 Baxter International Inc. Formulation d'argatroban
WO2008039473A2 (fr) 2006-09-27 2008-04-03 Scidose Llc Préparation sans alcool d'argatropan
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US7915290B2 (en) 2008-02-29 2011-03-29 Baxter International Inc. Argatroban formulations and methods for making and using same
US20090221637A1 (en) * 2008-02-29 2009-09-03 Baxter International Inc. Solid-state salt argatroban formulations and methods for producing and using the same
CN101598725B (zh) * 2009-06-23 2012-07-18 南通大学附属医院 阿加曲班在血细胞和生化常规分析中的应用
KR20140012029A (ko) 2010-10-21 2014-01-29 알티유 파머수티컬즈, 엘엘시 즉시 사용가능한 케토로락 제제
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
CN102120026A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以醇作为增溶剂的21(s)阿加曲班静脉注射液
CN102228677A (zh) * 2011-06-17 2011-11-02 天津市炜杰科技有限公司 以酸作为增溶剂的21(r)阿加曲班静脉注射液
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
US10537535B2 (en) * 2015-12-04 2020-01-21 The Regents Of The University Of California Histone deacetylase inhibitors
CN107773533A (zh) * 2016-08-26 2018-03-09 四川科瑞德制药股份有限公司 一种新型凝血酶抑制剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420919B (sv) * 1973-08-13 1981-11-09 Mitsubishi Chem Ind Forfarande for framstellning av n?722-dansyl-l-argininderivat och farmaceutiskt godtagbara syradditionssalter derav
US5214052A (en) * 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
CA2091715A1 (fr) * 1992-03-18 1993-09-19 Mitsubishi Kasei Corporation Preparations d'argatroban pour usage ophtalmique
US5506241A (en) * 1992-03-18 1996-04-09 Mitsubishi Chemical Corporation Argatroban preparations for ophthalmic use
JPH06219948A (ja) * 1993-01-25 1994-08-09 Mitsubishi Kasei Corp 抗トロンビン剤及びその製造方法
JPH06219949A (ja) * 1993-01-25 1994-08-09 Mitsubishi Kasei Corp 抗トロンビン剤及びその製造方法
TW256831B (fr) 1993-04-22 1995-09-11 Senju Pharma Co
JPH07228532A (ja) * 1993-04-22 1995-08-29 Senju Pharmaceut Co Ltd 水性液剤、その有効成分の溶解性向上方法および安定化方法
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
FR2715566B1 (fr) * 1994-02-03 1996-03-08 Synthelabo Solutions aqueuses concentrées d'argatroban.
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
JPH10316569A (ja) * 1997-05-19 1998-12-02 Mitsubishi Chem Corp アルガトロバンの可溶化方法及びそれによるアルガトロバン含有外用水性薬剤
KR101010547B1 (ko) * 2003-03-20 2011-01-24 미쓰비시 타나베 파마 코퍼레이션 알기닌아미드류를 함유하는 의약 제제
WO2005009361A2 (fr) 2003-07-17 2005-02-03 Smithkline Beecham Corporation Methode de traitement a l'argatroban pour des patients souffrant de thrombocytopenie induite par l'heparine
WO2007027565A2 (fr) * 2005-09-01 2007-03-08 Baxter International Inc. Formulation d'argatroban

Also Published As

Publication number Publication date
KR20140009599A (ko) 2014-01-22
JP5189980B2 (ja) 2013-04-24
CA2617920A1 (fr) 2007-03-08
IN2015DN03947A (fr) 2015-10-02
IL189290A (en) 2011-10-31
EP1948133A2 (fr) 2008-07-30
US8034830B2 (en) 2011-10-11
EP1948133B1 (fr) 2011-06-29
US7642271B2 (en) 2010-01-05
KR101753949B1 (ko) 2017-07-04
SI1948133T1 (sl) 2011-08-31
RU2416393C2 (ru) 2011-04-20
KR20150108430A (ko) 2015-09-25
MX2008002177A (es) 2008-04-22
CN101257890A (zh) 2008-09-03
HK1178053A1 (en) 2013-09-06
JP2009507018A (ja) 2009-02-19
WO2007027565A3 (fr) 2007-10-04
BRPI0616127B8 (pt) 2021-05-25
BRPI0616127B1 (pt) 2020-05-12
HK1123193A1 (en) 2009-06-12
US20070049617A1 (en) 2007-03-01
AU2006285097B2 (en) 2011-08-18
CY1112109T1 (el) 2015-11-04
RU2008112311A (ru) 2009-10-10
WO2007027565A2 (fr) 2007-03-08
CA2617920C (fr) 2014-05-27
BRPI0616127A2 (pt) 2011-06-07
CN101257890B (zh) 2012-10-31
KR20080042155A (ko) 2008-05-14
PT1948133E (pt) 2011-08-01
US20100099706A1 (en) 2010-04-22
US20100099705A1 (en) 2010-04-22
IL208183A0 (en) 2010-12-30
CN102895179A (zh) 2013-01-30
ATE514416T1 (de) 2011-07-15
CN102895179B (zh) 2014-10-22
PL1948133T3 (pl) 2012-03-30
ES2368758T3 (es) 2011-11-22
NZ565821A (en) 2010-05-28
IL189290A0 (en) 2008-06-05
AU2006285097A1 (en) 2007-03-08
US7985757B2 (en) 2011-07-26
DK1948133T3 (da) 2011-10-03

Similar Documents

Publication Publication Date Title
IL208183A0 (en) Argatroban formulation
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
AU2013334740A8 (en) Stable, low viscosity antibody formulation
MY149181A (en) Isoxazoline derivative and preparation process thereof
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
WO2011056985A3 (fr) Composés hétérocycliques substitués
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
EA201071167A1 (ru) Стабилизированные олеосомные композиции и способы их получения
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
DE602006017724D1 (de) Salicylsäurederivate
TNSN07435A1 (en) Novel piperidine carboxylic acid amide derivatives
NO20085213L (no) Nye pyridinanaloger
NO20084478L (no) Konjugerte lipidderivater
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
IN2011KN05169A (fr)
NO20080650L (no) Forbindelser omfattende DMXAA for behandling av kreft
IL169496A0 (en) Imino acid derivatives for use as inhibitors of matrix metalloproteinases
CY1107277T1 (el) Βενζισοξαζολες
WO2007039821A3 (fr) Nouveaux inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine et dans des cosmetiques
BR112012022442A2 (pt) processo para a preparação de um polimorfo de ranelato de estrôncio
WO2009148288A3 (fr) COMPOSITION POUR PRÉVENIR ET TRAITER DES MALADIES IMMUNITAIRES, CONTENANT UN NOUVEAU COMPOSÉ D'α-ISO-CUBÈBÈNE EXTRAIT DE SCHISANDRA CHINENSIS EN TANT QU'INGRÉDIENT ACTIF
UA95909C2 (en) Piperidine carboxylic acid amide derivatives
TH107162A (th) อิมัลชันของลิพิดที่เสถียรซึ่งมีพรอสทาแกลนดิน e1
UA44519U (ru) Производные 5-гетерил-1,2,4-триазол-3-илтио-ацетатной кислоты, которые проявляют гипохолестеринемическую активность